Safety and tolerability of Miltuximab® - a first in human study in patients with advanced solid cancers

Objective(s): Miltuximab® is a chimeric antibody targeting Glypican-1 (GPC-1), a cell surface antigen which is overexpressed in solid cancers. Miltuximab® has shown promising safety and efficacy in radioimmunotherapy models of prostate cancer. This first in human study used Miltuximab® radiolabelled...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Dhanusha Sabanathan, Douglas Campbell, Vicki Velonas, Sandra Wissmueller, Hubert Mazure, Marko Trifunovic, Pirooz Poursoltan, Kevin Ho-Shon, Tiffany Mackay, Maria Lund, Yanling Lu, Paul Roach, Dale Bailey, Bradley Walsh, David Gillatt, Howard Gurney
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Mashhad University of Medical Sciences 2021-07-01
coleção:	Asia Oceania Journal of Nuclear Medicine and Biology
Assuntos:	miltuximab® monoclonal antibody theranostic solid tumours glypican-1
Acesso em linha:	https://aojnmb.mums.ac.ir/article_18091_b4973c069eb12d3a20aec24ad0ceaeb8.pdf
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!